Clinical trial for S1P1 agonist program aimed at MS
Posted: Thu Jan 27, 2011 11:37 pm
Receptos, Inc., announced that their highly selective sphingosine-1-phosphate receptor 1 (S1P1) agonist, RPC1063, has been administered to the first subject in a single-ascending and multiple-ascending dose design Phase 1 clinical safety study.
The study is being conducted in healthy male and female volunteers at a single site in the United States under an Investigational New Drug (IND) application recently allowed by the FDA. Receptos is developing RPC1063 as a potential treatment for multiple sclerosis.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1397